| pubmed-article:16888761 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16888761 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:16888761 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:16888761 | lifeskim:mentions | umls-concept:C0032952 | lld:lifeskim |
| pubmed-article:16888761 | lifeskim:mentions | umls-concept:C0078257 | lld:lifeskim |
| pubmed-article:16888761 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:16888761 | pubmed:dateCreated | 2006-8-30 | lld:pubmed |
| pubmed-article:16888761 | pubmed:abstractText | Ultimately, patients with metastatic prostate cancer progress on androgen ablation therapy. The investigation of new chemotherapeutic regimens for the treatment of androgen-independent prostate cancer (AIPC) is essential. The authors conducted a Phase II trial with vinorelbine, doxorubicin, and daily prednisone (NAP) to investigate the antitumor activity and palliative response of this regimen in patients with AIPC. | lld:pubmed |
| pubmed-article:16888761 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16888761 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16888761 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:16888761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16888761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16888761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16888761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16888761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16888761 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16888761 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16888761 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:16888761 | pubmed:author | pubmed-author:TortiFrank... | lld:pubmed |
| pubmed-article:16888761 | pubmed:author | pubmed-author:HallM CraigMC | lld:pubmed |
| pubmed-article:16888761 | pubmed:author | pubmed-author:ClarkPeter... | lld:pubmed |
| pubmed-article:16888761 | pubmed:author | pubmed-author:BordenLester... | lld:pubmed |
| pubmed-article:16888761 | pubmed:author | pubmed-author:LovatoJamesJ | lld:pubmed |
| pubmed-article:16888761 | pubmed:author | pubmed-author:StindtDianaD | lld:pubmed |
| pubmed-article:16888761 | pubmed:author | pubmed-author:HarmonMichele... | lld:pubmed |
| pubmed-article:16888761 | pubmed:author | pubmed-author:M... | lld:pubmed |
| pubmed-article:16888761 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16888761 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16888761 | pubmed:volume | 107 | lld:pubmed |
| pubmed-article:16888761 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16888761 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16888761 | pubmed:pagination | 1093-100 | lld:pubmed |
| pubmed-article:16888761 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:meshHeading | pubmed-meshheading:16888761... | lld:pubmed |
| pubmed-article:16888761 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16888761 | pubmed:articleTitle | Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. | lld:pubmed |
| pubmed-article:16888761 | pubmed:affiliation | Department of Urology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. | lld:pubmed |
| pubmed-article:16888761 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16888761 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16888761 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16888761 | lld:pubmed |
